The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affecting BRAF and RAS proto-oncogenes in all stages of thyroid cancer. Initially identified by traditional sequencing approaches, the NGS studies also confirmed the acquisition of alterations that inactivate tumor protein p53 (TP53) and activate phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced thyroid cancers. Novel alterations, such as those in telomerase reverse transcriptase (TERT) promoter and mating-type switching/sucrose non-fermenting (SWI/SNF) complex, are also likely to promote progression of the BRAF V600E -driven thyroid cancers. A number of genetically engineered mouse models (GEMM) of BRAF V600E -driven thyroid cancer have been developed to investigate thyroid tumorigenesis mediated by oncogenic BRAF and to explore the role of genetic alterations identified in the genomic analyses of advanced thyroid cancer to promote tumor progression. This review will discuss the various GEMMs that have been developed to investigate oncogenic BRAF V600E -driven thyroid cancers.
INTRODUCTION
Cancers that originate from thyroid follicular cells, which are the cells in the thyroid responsible for producing thyroid hormones, can be classified into two main groups: differentiated and undifferentiated. The differentiated consist of follicular and papillary, the latter of which account for the vast majority of thyroid cancer cases. In many cases there is a step-wise progression from differentiated thyroid cancers to undifferentiated cancers. The progression is accompanied by a marked difference in prognosis. Most differentiated cancers are well controlled through surgery and radioiodine therapy. By contrast, the undifferentiated cancers do not respond to radioiodine and commonly have metastasis, limiting the effectiveness of surgery. The gainof-function BRAF V600E is the most common oncogenic driver in thyroid cancers. The canonical signaling pathway activated by BRAF is thought to result in the near exclusive activation of MEK and ERK. Most undifferentiated thyroid cancers are thought to arise from preexisting well-differentiated tumors as a result of acquiring additional alterations. Genomic analysis of advanced thyroid cancers has identified a number of genes that cooperate with oncogenic BRAF to promote thyroid cancer pro-
GENOMICS OF BRAF V600E -DRIVEN THYROID CANCERS
In the recent years, several studies in large cohorts of patients, encompassing the full spectrum of human thyroid cancers, from well-differentiated to undifferentiated, have defined the genomic landscape of these tumors [1] [2] [3] [4] [5] . These reports provided snapshots of the genetic makeup of papillary thyroid carcinoma (PTC), poorly-differentiated thyroid carcinoma (PDTC), and anaplastic thyroid cancers (ATCs), and gave insights into the key genetic alterations that promote thyroid cancer progression. Mutations in BRAF V600E are tumor-initiating events, occur in roughly half of all thyroid tumors, and are common in both well-differentiated (such as PTC) and advanced cancers (PDTC and ATC). Table 1 and Fig. 1 summarize the crucial genetic events that distinguish PTCs from PDTCs and ATCs. The role of some of these alterations in thyroid cancer progression has been demonstrated in vitro and in vivo (e.g., tumor protein p53
[TP53] loss-of-function, activation of phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K]/AKT pathway), whereas the precise mechanisms by which others contribute to this process remains to be tested. Mutations in TP53 gene, which typically inactivate the p53 protein, are extremely rare events in PTCs, whereas they occur in at least 50% of ATCs. Hotspot mutations in the proximal promoter of the telomerase reverse transcriptase (TERT) gene are the second most consistently associated genetic alteration in thyroid cancer progression: they occur in 11% of BRAF V600E -mutant PTCs, 44% of PDTCs, and 55% of ATCs. The fact that most of TERT mutations in PTCs are subclonal, whereas all of them are clonal events in PDTCs and ATCs suggests that these lesions are selected during thyroid cancer progression. Activating mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), usually affecting key residues in the protein's helical (E542K, E545K) and kinase (H1047R) domains are strongly associated with BRAF V600E -mutant tumors, and track with thyroid cancer progression. The former points to activation of PI3K/AKT pathway as an important process in these tumors, further reinforced by the occasional presence of AKT1 and AKT2 oncogenic mutations (e.g., E17K). However, the observation that truncating mutations in phosphatase and tensin homolog (PTEN) gene are relatively common in non-BRAF V600E advanced thyroid tumors but mutually-exclusive with their BRAF V600E -mutant counterparts suggests that the precise mechanism by which PI3K/AKT pathway is activated Finally, it is reasonable to think that the generalization of whole-exome and whole-genome sequencing technologies will eventually unmask novel alterations contributing to BRAF V600E -mutant thyroid cancer progression, but these will likely affect a small proportion of cases.
THYROID CANCERS AND THE MAPK PATHWAY
A large number of studies (reviewed in [6] ), including the next generation sequencing studies of advanced thyroid cancers described above, have demonstrated that carcinomas arising from thyroid follicular cells have non-overlapping activating mutations of the growth factor receptors RET or neurotrophic receptor tyrosine kinase 1/3 (NTRK1/3), the three isoforms of RAS (N, H, and K), or of BRAF, which altogether are found in approximately 70% of cases. The fact that all of these alterations activate the mitogen-activated protein kinase (MAPK) pathway highlights its importance in thyroid cancer biology. This has been confirmed through pharmacological and genetic targeting of BRAF and MEK in both preclinical [7] [8] [9] [10] and clinical studies [11, 12] . As BRAF V600E is the most common alteration that activates the MAPK pathway in thyroid cancers, a number of mouse models of thyroid cancers driven by oncogenic Braf have been developed (Table 2 ) [8, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , providing valuable insight into the biology of thyroid cancer driven by this oncoprotein. In the subsequent sections the various mouse models are discussed.
MOUSE MODELS OF BRAF V600E -INDUCED PTCs
The identification of BRAF V600E in papillary thyroid microcarcinoma (reviewed in [25] ) suggests that it is likely an initiating event in thyroid cancer. This hypothesis was first tested by Knauf et al. [13] , using the bovine thyroglobulin promoter to drive thyroid-specific expression of a human BRAF V600E cDNA (Tg-Braf). In this study, two mouse lines were created, Tg- Copyright © 2019 Korean Endocrine Society BRAF2 and Tg-BRAF3. Both lines developed PTCs, albeit with different latency and penetrance, which was attributed to differences in BRAF V600E expression, confirming that oncogenic BRAF alone was able to promote PTC development [13] . Similar results were obtained by Rusinek et al. [14] who generated three different lines with thyroglobulin-driven expression of human influenza hemagglutinin (HA)-tagged human BRAF V600E .
In these two models, BRAF V600E was overexpressed and not under control of its endogenous promoter. In addition, expression of the oncoprotein promoted thyroid dedifferentiation resulting in decreased expression of genes involved in thyroid hormone production, which includes Tg. Since the Tg promoter drives expression of the transgenic BRAF in these models, it is likely that expression of the oncoprotein attenuates its own expression, creating a complex negative feedback loop. To overcome this, Franco et al. [15] , used lox-stop-lox (LSL)-Braf V600E mice which contains a Cre-regulated conditional Braf V600E knock-in allele.
Crossing these mice with thyroid peroxidase (TPO)-Cre mice generated animals with thyroid-specific expression of Braf V600E under control of the endogenous Braf promoter, which is expected to begin around embryonic day 14. The resulting LSLBraf V600E /TPO-Cre mice developed PTCs with a near 100% In all of the models above, thyroid-specific expression of oncogenic BRAF was associated with decreased thyroid function and an increase in serum thyroid-stimulating hormone (TSH) levels, raising the possibility that signaling via the TSH receptor cooperates with oncogenic Braf. Indeed, Franco et al. [15] demonstrated that crossing the LSL-Braf V600E /TPO-Cre mice with TSH receptor knockout mice resulted in a marked delay in PTC formation. However, suppression of TSH by high doses of T4 starting shortly after birth, when the thyroid still had a normal histology, was not able to suppress tumorigenesis [15] . The reason for this was not investigated but could possibly be because T4 was administered after the Braf-expressing cells had already become refractory to TSH action. Alternatively, since unliganded TSH receptor retains significant constitutive activity [26] , absence of ligand alone may not be sufficient to block the pathway. Consistent with amplified TSH receptor signaling not being required for Braf V600E -induced thyroid tumorigenesis is the observation that focal activation of Braf V600E in the thyroid of Braf CA mice by either leaky Cre activity from the Tg-CreER T2 allele [16] or thyroid injection of adenovirus expressing Cre recombinase under the control of the thyroglobulin promoter [17] resulted in PTCs despite not elevating TSH. Expression of BRAF V600E in the immortal differentiated rat thyroid cell line, PCCL3, blocks thyroid differentiation, which can be reversed by inhibition of the MAPK pathway [27, 28] . This observation was first confirmed in vivo by Chakravarty et al. [18] , who demonstrated that thyroid-specific, dox-inducible expression of BRAF V600E blocked thyroid differentiation and generated radioactive iodide (RAI)-refractory PTCs. Consistent with in vitro data, this was completely reversible by genetic inhibition of BRAF
V600E
, and partially by pharmacological inhibition of RAF or MEK [18] . These data ultimately led to a clinical trial testing the MEK inhibitor selumetinib in RAI-refractory thyroid cancers, demonstrating restoration of iodide uptake that was sufficient to justify treating with RAI in eight of 20 patients [29] . Selumetinib restored uptake in all five patients harboring a NRAS mutation, but only in one of nine BRAF V600E -positive patients. The difference observed between RAS-mutant and BRAFmutant tumors was suggested to be due to incomplete inhibition of the MAPK pathway in the BRAF-mutant tumors as a result of higher flux through the pathway. This hypothesis was supported by Nagarajah et al. [19] , who demonstrated selumetinib was ineffective at restoring thyroid differentiation in LSL-Braf V600E / TPO-Cre mice, but the more potent MEK inhibitor CH5126766 was able to restore differentiation and responsiveness to RAI. CH5126766 is an allosteric inhibitor of MEK that, upon binding, places MEK in an inactive complex with RAF, and thus functions as a RAF/MEK dual inhibitor [30] . In human clinical trials, the RAF inhibitors dabrafenib and vemurafenib, which are more effective than selumetinib in blocking the MAPK pathway, restored iodide uptake sufficiently to justify treating with RAI in six of 10 patients and four of 10 BRAF V600E -mutant patients, respectively [31, 32] .
THYROID CANCER PROGRESSION AND PI3K PATHWAY
Alterations in effectors of the PI3K pathway are found in approximately 38% of advanced thyroid cancer harboring BRAF V600E (Table 1, Fig. 1 ). Activating mutations of PIK3CA (32%) are the most common, followed by AKT1 and AKT2 (Fig. 1) inhibitor would improve the efficacy of this combination.
INACTIVATION OF TRP53
As shown in Fig. 1 showed accelerated tumor growth, shorter survival, and histologic features associated with poor prognosis in human PTC [21] . In addition, 50% of the tumors in older animals showed progression to PDTC or ATC, which was not observed in TPOCreER T2 /Braf CA/+ mice. Homozygous inactivation of Trp53 further accelerated progression to ATC, which was accompanied by a decrease in survival. The authors report a modest but significant decrease in survival of tamoxifen-treated TB270/FL compared to TBP; however, the study was not designed to control for other factors that may contribute to this difference (i.e., tamoxifen dose, animal background These three mouse models have differences in ATC latency, which is likely in part due to timing of oncogene activation and Trp53 loss. The ATCs in all three models were very similar to human ATCs, with histological analysis showing pleomorphic giant cells and spindle cells, high mitotic rate, and local invasion. In humans, BRAF V600E ATCs often coexist with a PTC component, which is seen in both TBP and TPO-Braf V600E -
Trp53
-/-mice. By contrast, a PTC component was not observed
in BRAF/p53 mice. The reason for this difference is unclear, but a possible explanation is the timing of genetic changes. In TBP mice, loss of p53 and activation of Braf occur simultaneously in adults, whereas in BRAF/p53 animals, thyroid-specific Trp53 inactivation occurs late in embryonic development, followed by expression of oncogenic protein when the animals are adults. Similar to human ATCs, in all models, ATC bearing mice had a short survival and lung metastasis were frequently found in both TBP (19%) and BRAF/p53 (50%) mice [8, 21] . Frequency of lung metastasis was not investigated in the TPO-Braf V600E -
-/-mice.
In humans, RAF inhibitors have shown efficacy in BRAF V600E ATC, which is further improved by combining it with MEK inhibitors [11, 12] . Indeed, the combination of RAF and MEK inhibitors dabrafenib and trametinib has recently been FDA-approved for the treatment of BRAF V600E positive ATCs [11] . In TBP mice, the RAF inhibitor PLX4720 induced a partial response in the PTC-bearing thyroid gland, but the ATC component continued to grow. There was also a modest extension of survival with the RAF inhibitor with all animals progressing within 35 days after starting treatment. In BRAF/p53 mice, PLX4720 did not have an effect, and cell lines generated from TPO-Braf
V600E
-Trp53 -/-mice were resistant to RAF inhibitors.
As in humans, treating murine ATCs in both TBP and BRAF/ p53 with RAF and MEK inhibitor combination produced a more potent inhibition of the MAPK pathway and marked tumor regression that improved survival. Nevertheless, more than half of the TBP animals succumbed to the disease after approximately 70 days of treatment. Time to progression of BRAF/p53 mice treated with CH5126766 was not determined, but given that after genetic inhibition of BRAF V600E ,which produced a near complete tumor regression, nearly all animals recurred [8] , it is reasonable to think that mice treated with CH5126766 would also progress. In melanoma patients, multiple mechanisms of acquired resistance to RAF inhibitors as well as RAF/MEK inhibitor have been identified (reviewed in [37] [38] [39] [40] -positive PTC with acquired resistance to vemurafenib [44] , there is no information on the mechanisms of acquired resistance of BRAF-mutant thyroid cancers to RAF kinase inhibition. Knauf et al. [8] Whole exome sequencing identified recurrent focal amplifications of Met in 45% of the recurrent tumors as well as an activating mutation of Hras [8] . The Met-amplified recurrences overexpressed the receptor as well as its ligand hepatocyte growth factor (Hgf), and were exquisitely sensitive to MET kinase inhibitors, which was required for activation of the MAPK pathway [8] .
While it remains to be demonstrated in human thyroid cancers, it seems likely that acquired resistance of BRAF V600E -positive thyroid cancers to RAF and RAF/MEK inhibitors will center around the reactivation of the MAPK pathway as seen in melanomas [37] [38] [39] [40] , which likely explains the improved response of ATCs to RAF/MEK inhibitor combination compared to RAF inhibitors alone [11, 12] . It will be important to determine events driving acquired resistance to RAF and RAF/MEK inhibitors in humans, especially for the latter, which is now FDA-approved in BRAF V600E -positive ATCs.
The ATCs in the BRAF/p53 mice are heavily infiltrated with macrophages [8] , which are almost universally found in their human counterparts [45] . Macrophage infiltration was not investigated in the ATCs from TBP or TPO-Braf V600E -Trp53 -/-mice. However, immune deconvolution of transcriptomic data with CIBERSORT [46] demonstrated a similar increase in macrophages of ATCs from TBP to those from BRAF/p53 mice (Fig. 2) . Macrophages have been suggested to promote tumor progression by stimulating angiogenesis [47, 48] and lymphangiogenesis, enhancing chemoresistance [49] [50] [51] , promoting distant metastases [52] [53] [54] [55] [56] , and creating an immune suppressive microenvironment. In human thyroid cancers, macrophage infiltration is associated with decreased survival in both PDTCs and ATCs [45, 57] . Depletion of macrophages in mouse models of BRAF-induced PTC attenuated tumor formation and restored a thyroid follicular architecture [58] . The effect of macrophage depletion on ATCs has yet to be investigated in either mouse models or human trials. Results in other cancers suggest that depletion of macrophages alone is unlikely to have profound or sustained anti-tumor effects but is likely to improve the efficacy of chemo-, targeted or immuno-therapies. The recent demonstration that inhibition of PI3Kγ promotes a change in macrophage polarization from M2-like to M1-like, which is associated with a markedly improved response to immune checkpoint blockade [59, 60] , suggest altering macrophage polarization may be an effective alternative to macrophage depletion. As ATCs are frequently infiltrated with both exhausted T-cells [61] [62] [63] and macrophages [45, 64] , this combination might have efficacy in this aggressive disease. Human ATCs have been demonstrated to also be infiltrated with programmed cell death 1 (PD1)-positive T-cells, programmed death ligand 1 (PD-L1)-expressing macrophages, and possibly myeloid derived suppressor cells (MDSCs). Expression of PD1 and PD-L1 has been found to be associated with a positive response to anti-PD1/PD-L1 immunotherapies, whereas infiltration of the immune suppressive MDSCs and macrophages would be expected to promote resistance to immune therapies. Currently it has not been reported whether the mouse models of ATC also replicate the T-cell infiltrate, MDSC, PD1, or PD-L1 positivity of human ATCs. In the age of immunotherapy, it will be essential to expand our knowledge of the tumor microenvironment of human and mouse ATCs to guide investigators on how to best use the mouse models to understand the effects of the complex tumor microenvironment in ATCs on the response to immune therapies and improve the efficacy of immune therapies in advanced thyroid cancers. 
CONCLUSIONS
Genomic analysis of thyroid cancers at different stages of progression has identified several strong candidates for promoting progression of BRAF V600E -driven PTCs to ATCs (Table 1 , Fig.   1 ). Of these, activation of Pik3ca and loss of Trp53 have been demonstrated to be sufficient to drive thyroid cancer progression in mouse models (Table 2) . Probably due to its genetic simplicity, there is an excellent concordance between the alterations driving BRAF
V600E
-mutant progression in thyroid cancer patients and the murine models created to mimic these genetic events. This strongly suggests that results from genomic studies in large cohorts of advanced thyroid cancer patients should inform future approaches involving genetically engineered mouse model research. It also attests to the efficacy of these in vivo models to become essential tools to test pharmacological combinations that can be ultimately tested in appropriate clinical trials.
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